STAREE: atorvastatin cut major CV events 30% in adults 70+ with no rise in dementia
A quoted summary of the STAREE trial in NEJM: 9,971 adults aged 70 or older without cardiovascular disease, diabetes or dementia were randomized to atorvastatin 40 mg or placebo for a median 5.9 years. Atorvastatin cut major cardiovascular events 30% and MI and revascularization 43% each, with no significant increase in dementia or all-cause mortality and equal serious adverse events.
